SMC does not accept use of agomelatine (Valdoxan®) within NHSScotland

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

SMC does not accept use of agomelatine (Valdoxan®) within NHSScotland

Source: Scottish Medicines Consortium (SMC)

Date published: 10/11/2009 15:55

Summary

by: Yuet Wan

The Scottish Medicines Consortium (SMC) did not accept for use within NHSScotland agomelatine (Valdoxan®) for the treatment of major depressive episodes in adults, as the manufacturer did not present a sufficiently robust economic analysis.

About this library entry

Category: 4.3.4 Other antidepressant drugs | Clinical guidelines | Mood disorders (including depression) | Scottish Medicines Consortium

NeLM area: Evidence > Drug Specific Reviews

Link

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.

Printer Friendly Version

Related evidence

4.3.4 Other antidepressant drugs

31/12/2011

Mirtazapine versus other antidepressive agents for depression

16/02/2011

Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis

14/09/2010

SMC does not recommend agomelatine (Valdoxan®) for major depressive episodes

Mood disorders (including depression)

12/01/2012

AWMSG issues Final Appraisal Recommendation on the use of sodium valproate (Episenta®) for the treatment of manic episode in bipolar disorder

31/12/2011

Oxcarbazepine for acute affective episodes in bipolar disorder

31/12/2011

Mirtazapine versus other antidepressive agents for depression

Back